AI Summary
Thinking
Thinking
We reviewed 39 live results for hyrimoz adalimumab and narrowed them down to the 3 options that look most worth comparing first.
The options are Hyrimoz (adalimumab-adaz), Hyrimoz (Adalimumab) and Hyrimoz (Adalimumab).
Source: Sandoz
Description
Hyrimoz is an FDA-approved adalimumab biosimilar and TNF blocker used as a subcutaneous injection to treat inflammatory diseases. It is commonly prescribed for patients with rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. As a biologic therapy, it helps reduce inflammation and manage symptoms by targeting tumor necrosis factor (TNF) proteins in the body.
Best for
rheumatoid arthritis patients, Crohn's disease therapy, plaque psoriasis treatment, chronic inflammation management and biologic therapy users
Rate this product
Source: Sandoz Singapore Pte. Ltd.
Description
Hyrimoz is a biologic DMARD and TNF-alpha blocker, functioning as a biosimilar to adalimumab. In Singapore, it is indicated for the treatment of various autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease. It helps manage the immune system's response to reduce inflammation and prevent joint damage.
Best for
rheumatoid arthritis patients, Crohn’s disease management, biologic therapy seekers and ankylosing spondylitis treatment
Rate this product
Source: Sandoz Philippines Corporation
Description
Hyrimoz is a TNF-alpha inhibitor biosimilar used to treat various autoimmune and inflammatory conditions within the field of immunology.
Best for
autoimmune conditions, inflammatory disease management and rheumatology patients
Rate this product
| Compare | #1Hyrimoz (adalimumab-adaz) | #2Hyrimoz (Adalimumab) | #3Hyrimoz (Adalimumab) |
|---|---|---|---|
| Source | Sandoz | Sandoz Singapore Pte. Ltd. | Sandoz Philippines Corporation |
| Description | Hyrimoz is an FDA-approved adalimumab biosimilar and TNF blocker used as a subcutaneous injection to treat inflammatory diseases. It is commonly prescribed for patients with rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. As a biologic therapy, it helps reduce inflammation and manage symptoms by targeting tumor necrosis factor (TNF) proteins in the body. | Hyrimoz is a biologic DMARD and TNF-alpha blocker, functioning as a biosimilar to adalimumab. In Singapore, it is indicated for the treatment of various autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease. It helps manage the immune system's response to reduce inflammation and prevent joint damage. | Hyrimoz is a TNF-alpha inhibitor biosimilar used to treat various autoimmune and inflammatory conditions within the field of immunology. |
| Best for | rheumatoid arthritis patients, Crohn's disease therapy, plaque psoriasis treatment, chronic inflammation management and biologic therapy users | rheumatoid arthritis patients, Crohn’s disease management, biologic therapy seekers and ankylosing spondylitis treatment | autoimmune conditions, inflammatory disease management and rheumatology patients |
| Action | Sandoz | Sandoz Singapore Pte. Ltd. | Sandoz Philippines Corporation |
| Rate this product |
"Hyrimoz (adalimumab-adaz) from Sandoz."
TopFind picked this because Hyrimoz is a trusted, clinically validated biosimilar registered with the Thai FDA, providing an effective alternative to the reference biologic for chronic inflammatory management.
Note: TopFind AI compiles product and service information for general comparison purposes only.